Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects

British Journal of Clinical Pharmacology

Volumn 64, Issue 1, 2007, Pages 67-74

  Zhang, Yifan ^a   Si, Dayong ^b   Chen, Xiaoyan ^a   Lin, Nan ^a   Guo, Yingjie ^b   Zhou, Hui ^b   Zhong, Dafang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Clinical pharmacokinetics; CYP2C19; CYP2C9; Gliclazide; Polymorphism

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; GLICLAZIDE; GLUCOSE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMOZYGOTE; HUMAN; HYPOGLYCEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC;

EID: 34250661722     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02846.x     Document Type: Article

References (24)

1. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998 45 : 525 38.
2. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome CYP2C19 genetic polymorphism. Clin Pharmacokinet 2002 41 : 913 58.
3. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005 60 : 418 22.
4. Si DY, Guo YJ, Zhang YF, Zhou H, Zhong DF. Identification of a novel variant of CYP2C9 allele in Chinese. Pharmacogenetics 2004 14 : 465 9.
5. Zhang YF, Zhong DF, Si DY, Guo YJ, Chen XY, Zhou H. Lornoxiam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol 2005 59 : 14 7.
6. Guo YJ, Zhang YF, Wang Y, Si DY, Chen XY, Zhong DF, Fawcett JP, Zhou H. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metab Dispos 2005 33 : 749 53.
7. Guo YJ, Wang Y, Si DY, Fawcett PJ, Zhong DF, Zhou H. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005 35 : 853 61.
8. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996 6 : 521 6.
9. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the effective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 64.
10. Palmer KJ, Brogden RN. Gliclazide, an update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus. Drugs 1993 46 : 92 125.
11. Taylor AR, Brownsill RD, Grandon H, Lefoulon F, Petit A, Luijten W, Kopelman PG, Walther B. Synthesis of putative metabolism and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo (3,3,0) oct-3-yl)-3-(4 - methylphenylsulfonyl) urea], in diabetic patients. Drug Metab Dispos 1996 24 : 55 64.
12. Rieutord A, Stupans I, Shenfield GM, Gross AS. Gliclazide hydroxylation by rat liver microsomes. Xenobiotica 1995 25 : 1345 54.
13. Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 2003 74 : 334 40.
14. McGavin JK, Perry CM, Gua KL. Gliclazide modified release. Drugs 2002 62 : 1357 66.
15. Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003 52 : 29 34.
16. Delrat P, Paraire M, Jochemsen R. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biophar Drug Dispos 2002 23 : 151 7.
17. Wang SL, Huang J, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995 5 : 37 42.
18. Su J, Chen XY, Duan XT, Zhang YF, Zhong DF. Rapid determination of gliclazide in human plasma by LC/MS/MS. Chinese Pharmaceut J 2006 41 : 864 7.
19. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005 44 : 1209 25.
20. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphism affects the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 2005 78 : 370 7.
21. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmoller J. Impacts of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002 12 : 101 9.
22. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr., Koch P, Antonian L, Wagner GYuL, Parkinson A. Effects of prototypical microsomal enzyme inducers in cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003 31 : 421 31.
23. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000 68 : 401 11.
24. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006 16 : 497 514.